Xcout IntelMonte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Subscribe to see Monte Rosa Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Monte Rosa Therapeutics, Inc. at a glance
Monte Rosa Therapeutics, Inc. is a biotech company headquartered in Boston, United States. It is publicly listed (GLUE) with a market capitalisation of $878.7M. Xcout tracks 23 named people at Monte Rosa Therapeutics, Inc., including Markus Warmuth (President, Chief Executive Officer & Director).
Monte Rosa Therapeutics, Inc. leadership
- Markus WarmuthPresident, Chief Executive Officer & Director
- Christine SiuChief Operating Officer in Residence, BridgeBio
- Jennifer ChampouxChief Operating Officer
- Magnus WalterChief Technology Officer
- Magnus Walter DPHILChief Technology Officer
- Filip JankuChief Medical Officer
17 more named people on record for Monte Rosa Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Monte Rosa Therapeutics, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $48M | 13 named | |
| — | $32.5M | 14 named |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Get Monte Rosa Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Monte Rosa Therapeutics, Inc. in Xcout Intel
- 23 named people with titles, LinkedIn and board committees
- 2 funding rounds before the IPO with the investors in each, and who they co-invest with
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access